Product Registration - The company has received medical device registration certificates for four products from the National Medical Products Administration [1] - Two of the approved respiratory "small joint inspection" products offer high sensitivity, specificity, and ease of operation, providing reports in as fast as 30 minutes [1] - The "small joint inspection" series has now expanded to 10 products, enhancing the company's "6/3+X respiratory infection nucleic acid rapid detection" system [1] Clinical Impact - The approved respiratory products are crucial for early identification of pathogens in respiratory infections, which is vital for precise medication and reducing antibiotic resistance [1] - The EB virus nucleic acid detection kit has undergone significant technical upgrades, improving detection sensitivity and supporting various specimen types [2] - The CYP3A5 gene polymorphism nucleic acid detection kit is the ninth product in the company's drug genome series, aimed at optimizing clinical medication plans for transplant patients [2]

Core Viewpoint - The company has received medical device registration certificates from the National Medical Products Administration for four products, indicating regulatory approval and potential market entry [1] Group 1: Product Details - Two respiratory "small joint inspection" products have high sensitivity, high specificity, and ease of operation, capable of providing results in as fast as 30 minutes [1] - The products target major pathogens responsible for community-acquired pneumonia and pediatric respiratory infections, including Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis [1] - The company has upgraded its EB virus nucleic acid detection kit, enhancing detection sensitivity and supporting various specimen types such as plasma and whole blood [1] - The CYP3A5 gene polymorphism nucleic acid detection kit is designed to guide clinical medication plans for the core anti-rejection drug tacrolimus post-transplant [1]